Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExPEC9
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
ExPEC9 is a 9-valent conjugate vaccine candidate developed by Shandong Kunli Biopharmaceutical, targeting extraintestinal pathogenic Escherichia coli (ExPEC). The vaccine is designed to prevent a range of serious conditions caused by ExPEC, including urinary tract infections (UTI), sepsis, and neonatal meningitis, by inducing an immune response against nine specific E. coli serotypes. As a conjugate vaccine, it likely consists of bacterial polysaccharides chemically linked to a carrier protein to enhance its immunogenicity, particularly in vulnerable populations. It is currently in the preclinical stage of development.
- Other names
- 9价肠外致病性大肠埃希菌疫苗9-valent extraintestinal pathogenic E. coli vaccine
02
Targets
Extraintestinal pathogenic Escherichia coli O-antigen polysaccharide serotype O15Escherichia coli O16 O-antigen polysaccharideO18A (Escherichia coli O18A O-antigen polysaccharide)Extraintestinal pathogenic Escherichia coli O-antigen polysaccharide serotype O1AO2 antigen (Escherichia coli O2 antigen)O25b (Escherichia coli O25b antigen)Escherichia coli O4 O-antigen polysaccharideExtraintestinal pathogenic Escherichia coli O6A O-antigen polysaccharideO75 (Escherichia coli O75 O-antigen polysaccharide)EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on ExPEC9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExPEC9.